Head Office:
Parkveien 53 B
NO-0256 Oslo
Norway
Tel: +47 24 11 09 50
Fax: +47 24 11 09 51
Org.nr: 983 733 506 MVA
mail@clavispharma.com
Disclaimer
Clavis Pharma™ develops new and superior pharmaceuticals by leveraging the potential of its Lipid Vector Technology (LVT). The Company’s objective is to build an attractive pipeline of new drug candidates in oncology and subsequently license these out to strategic partners for further co-development and marketing. Revenues will be generated already at the time of partnering and onwards from up-front payments milestone payments and royalties from licensees.
Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").
New investigational drug also shown to improve remission rates and reduce short-term mortality compared to previous treatments.
in Clavis Pharma ASA on 15 July 2009 at 15:00 CET at Parkveien 55, Oslo, Norway
